Considering the role of these oncometabolites in intracellular and microenvironmental regulatory networks and their role in metabolic symbiosis it could be regarded that rapamycin and other developing mTOR inhibitors may have additional effects besides their anti-proliferative effects in different tumours with characteristic highly glycolytic phenotype, especially in case of IDH1 mutation (such as AML, gliomas, chondrosarcomas). The gene discussed is IDH1; the disease is glioma.